These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25358597)

  • 1. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.
    Zhang T; Shen H; Dong W; Qu X; Liu Q; Du J
    Sci Rep; 2014 Oct; 4():6855. PubMed ID: 25358597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
    Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.
    Cao H; Dong W; Shen H; Xu J; Zhu L; Liu Q; Du J
    PLoS One; 2015; 10(8):e0135844. PubMed ID: 26287334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor.
    Zheng H; Worrall C; Shen H; Issad T; Seregard S; Girnita A; Girnita L
    Proc Natl Acad Sci U S A; 2012 May; 109(18):7055-60. PubMed ID: 22509025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
    Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
    Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
    Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
    Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of IGF-1R in esophageal squamous cell carcinoma and the effect of its silencing by siRNA on the proliferation of esophageal cancer EC9706 cells in vitro].
    Ma W; Li W; Fan QX; Wang LX; Wang RL; Lu SX
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):609-12. PubMed ID: 22325222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
    Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
    Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
    Ma W; Zhang T; Pan J; Shi N; Fan Q; Wang L; Lu SH
    Oncol Rep; 2014 Oct; 32(4):1601-9. PubMed ID: 25175038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
    Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
    Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of SOD2 and β-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells.
    Zhang D; Cui Y; Niu L; Xu X; Tian K; Young CY; Lou H; Yuan H
    Eur J Cell Biol; 2014 Jul; 93(7):289-98. PubMed ID: 24939178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.
    Wang W; Zhang Y; Lv M; Feng J; Peng H; Geng J; Lin Z; Zhou T; Li X; Shen B; Ma Y; Qiao C
    J Ovarian Res; 2014 Nov; 7():103. PubMed ID: 25424625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
    Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1.
    Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
    Oncogene; 2008 Mar; 27(11):1629-38. PubMed ID: 17828296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
    Wojtalla A; Salm F; Christiansen DG; Cremona T; Cwiek P; Shalaby T; Gross N; Grotzer MA; Arcaro A
    PLoS One; 2012; 7(10):e47109. PubMed ID: 23056595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.